D. E. Shaw & Co., Inc. Nuvalent, Inc. Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Nuvalent, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 399,199 shares of NUVL stock, worth $39.6 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

399,199

Previous 445,382 10.37%

Holding current value

$39.6 Million

Previous $33.4 Million 9.45%

% of portfolio

0.03%

Previous 0.03%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$62.76 - $81.61 $2.9 Million - $3.77 Million	-46,183 Reduced 10.37%	399,199 $30.3 Million
Q1 2024 May 15, 2024	SELL	$72.35 - $88.99 $1.65 Million - $2.03 Million	-22,801 Reduced 4.87%	445,382 $33.4 Million
Q4 2023 Feb 14, 2024	BUY	$42.42 - $80.28 $6.4 Million - $12.1 Million	150,907 Added 47.56%	468,183 $34.5 Million
Q3 2023 Nov 14, 2023	BUY	$39.12 - $49.85 $957,696 - $1.22 Million	24,481 Added 8.36%	317,276 $14.6 Million
Q2 2023 Aug 14, 2023	BUY	$23.58 - $44.68 $1.9 Million - $3.6 Million	80,584 Added 37.97%	292,795 $12.3 Million
Q1 2023 May 15, 2023	SELL	$25.42 - $33.52 $1.08 Million - $1.43 Million	-42,657 Reduced 16.74%	212,211 $5.54 Million
Q4 2022 Feb 14, 2023	BUY	$18.46 - $36.37 $3.61 Million - $7.12 Million	195,733 Added 330.99%	254,868 $7.59 Million
Q3 2022 Nov 14, 2022	BUY	$13.55 - $19.92 $577,799 - $849,428	42,642 Added 258.55%	59,135 $1.15 Million
Q2 2022 Aug 15, 2022	BUY	$7.4 - $15.07 $122,048 - $248,549	16,493 New	16,493 $224,000
Q4 2021 Feb 14, 2022	SELL	$18.01 - $30.1 $218,677 - $365,474	-12,142 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$18.25 - $38.35 $221,591 - $465,645	12,142 New	12,142 $274,000

Others Institutions Holding NUVL

# of Institutions

178

Shares Held

56.6M

Call Options Held

527K

Put Options Held

131K

View Full List

About Nuvalent, Inc.

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $4.26B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

More about NUVL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account